Skip to content
OpenCapital
Get started

Opus Genetics IRD Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
——

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M—
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's increase (decrease) in prepaid expense and other assets?
Opus Genetics (IRD) reported increase (decrease) in prepaid expense and other assets of $2.14M in Q1 2026.
How has Opus Genetics's increase (decrease) in prepaid expense and other assets changed year-over-year?
Opus Genetics's increase (decrease) in prepaid expense and other assets increased by 147.3% year-over-year, from $865K to $2.14M.
What does increase (decrease) in prepaid expense and other assets mean?
The net change in payments made in advance for goods or services to be received in future periods. Monitoring this helps assess the company's near-term cash outflows and the timing of future expense recognition.